Overall, this work provides an integrated quantitative understanding of thrombocytopenia and the GDF-15 biomarker changes in response to HDM2 inhibitors, with potential use in dosing regimen optimisation and patient benefit. The gene discussed is MDM2; the disease is Thrombocytopenia.